Integer Holdings will be bought by KKR affiliates for $127 per share, valuing the transaction at about $5.7 billion. The cash premium of roughly 52% to the prior close gives shareholders immediate value and signals a shift to private ownership, removing the company from public markets.
Key Highlights
- KKR‑managed funds will acquire Integer Holdings in an all‑cash deal valued at $5.7 billion.
- The definitive agreement was signed on August 3 and the transaction is expected to close by year‑end pending shareholder approval and regulatory clearances.
- Upon closing, Integer will be delisted from the NYSE, become privately held, and launch an employee‑ownership program.
The transaction promises immediate liquidity for investors while ushering the medical‑device CDMO into private ownership, a move that could reshape its strategic flexibility.
$5.7B Sale Announcement
The definitive agreement signed on August 3 confirms that KKR‑managed investment funds will purchase Integer Holdings in an all‑cash deal. The board unanimously endorsed the transaction, citing a strategic review that examined multiple alternatives. The premium reflects confidence in Integer’s differentiated engineering platform and its position in cardio, vascular, and neuromodulation markets.
For shareholders, the cash consideration removes exposure to market volatility and provides a clear exit at a historically high valuation. The agreement also obliges the company to file a proxy statement, ensuring transparency as the deal progresses.
Deal Mechanics and Financing
K
The financing structure echoes prior large‑scale private‑equity buyouts in the healthcare sector, offering both capital efficiency and flexibility for future growth initiatives. Senior advisers to KKR include Centerview Partners, Barclays, Citi and Raymond James, while Kirkland & Ellis serves as legal counsel. Integer’s own advisers are Goldman Sachs for financial advice and Davis Polk & Wardwell for legal matters.
The absence of a financing contingency underscores the confidence of the investors and clears a major hurdle that often delays deal closure. Once completed, the company will operate as a privately held entity, shedding the reporting burdens of a public company.
Market Impact and Timing
By converting public equity into cash, the deal locks in gains for investors who have benefited from recent price appreciation. The premium also signals that KKR perceives substantial upside in Integer’s contract manufacturing capabilities, particularly as medical‑device innovation accelerates. Delisting from the NYSE will eliminate the liquidity premium and reduce the cost of capital, but it also removes the company from the public eye, concentrating value creation within a private framework.
Next Milestones
The transaction is slated to close by the end of the calendar year, contingent on shareholder approval and customary regulatory clearances. A proxy statement will be filed with the SEC, and a definitive vote is expected at the forthcoming shareholder meeting. Upon consummation, KKR intends to launch an employee‑ownership program, aligning staff incentives with the new private‑equity structure.
Investors should monitor the proxy voting outcome and any antitrust rulings that could affect timing. The year‑end closing will be the decisive event that determines whether Integer transitions smoothly into KKR’s portfolio or faces unforeseen obstacles.
Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...